表紙:副腎白質ジストロフィー:世界の治験動向
市場調査レポート
商品コード
750074

副腎白質ジストロフィー:世界の治験動向

Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Global Clinical Trials Review, H2, 2018

出版日: | 発行: GlobalData | ページ情報: 英文 73 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=114.86円
副腎白質ジストロフィー:世界の治験動向
出版日: 2018年10月25日
発行: GlobalData
ページ情報: 英文 73 Pages
納期: 即納可能 即納可能とは
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、副腎白質ジストロフィー治療薬の治験に関連する基本情報やデータを提供しており、試験件数および被験者の募集状況、段階別の動向、治験を実施している主な製薬企業および研究機関のプロファイルなどをまとめています。

当レポートの概要

調査範囲

各地域における治験状況

  • 各国の治験件数と平均被験者数
    • アジア太平洋地域の主要国における治験件数
    • 欧州の主要5ヶ国における治験件数
    • 北米の主要国における治験件数
    • 中南米の主要国における治験件数

G7諸国での治験件数:遺伝性疾患治療薬の治験における副腎白質ジストロフィーの割合

G7諸国における段階別の治験件数

G7諸国での治験件数:進捗状況別

E7諸国での治験件数:遺伝性疾患治療薬の治験における副腎白質ジストロフィーの割合

E7諸国における段階別の治験件数

E7諸国での治験件数:進捗状況別

段階別の治験件数

  • 進行中の治験:段階別

進捗状況別の治験件数

治験の目標の達成状況

一定期間に採用された被験者

スポンサーの種類別の治験件数

有望なスポンサー

副腎白質ジストロフィー治療薬の治験に携わっている主要企業

有望な薬剤

治験プロファイルの概要

付録

図表

List of Tables

  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics, Global, Clinical Trials by Region, 2018* 7
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 9
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018* 10
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2018* 11
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials, Europe, Top Five Countries, 2018* 12
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials, North America, Top Countries, 2018* 13
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials, Central and South America, Top Countries, 2018* 14
  • Proportion of Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) to Genetic Disorders Clinical Trials, G7 Countries (%), 2018* 16
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 17
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 19
  • Proportion of Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) to Genetic Disorders Clinical Trials, E7 Countries (%), 2018* 21
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics, E7 Countries, Clinical Trials by Phase, 2018* 22
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018* 23
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics, Global, Clinical Trials by Phase, 2018* 24
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics, Global, Clinical Trials In Progress by Phase 2018* 25
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics, Global, Clinical Trials by Trial Status, 2018* 27
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials, Global, by End Point Status, 2018* 28
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 29
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2018* 30
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 32
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 34
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018* 36

List of Figures

  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics, Global, Clinical Trials by Region (%), 2018* 7
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 8
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018* 10
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2018* 11
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2018* 12
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials, North America, Top Countries (%), 2018* 13
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2018* 14
  • Proportion of Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) to Genetic Disorders Clinical Trials, G7 Countries (%), 2018* 15
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 17
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 18
  • Proportion of Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) to Genetic Disorders Clinical Trials, E7 Countries (%), 2018* 20
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics, E7 Countries, Clinical Trials by Phase, 2018* 22
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018* 23
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics, Global, Clinical Trials by Phase (%), 2018* 24
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics, Global, Clinical Trials In Progress by Phase, 2018* 25
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics, Global, Clinical Trials by Trial Status, 2018* 26
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials, Global, by End Point Status, 2018* 28
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 29
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2018* 30
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 31
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 33
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018* 35
  • GlobalData Methodology 72
目次
Product Code: GDHC5372CTIDB

GlobalData's clinical trial report, "Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Global Clinical Trials Review, H2, 2018" provides an overview of Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) clinical trials scenario. This report provides top line data relating to the clinical trials on Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

Table of Contents 2

  • List of Tables 3
  • List of Figures 4
  • Report Guidance 5
  • GlobalData Clinical Trials Report Coverage 6
  • Clinical Trials by Region 7
  • Clinical Trials and Average Enrollment by Country 8
  • Top Countries Contributing to Clinical Trials in Asia-Pacific 11
  • Top Five Countries Contributing to Clinical Trials in Europe 12
  • Top Countries Contributing to Clinical Trials in North America 13
  • Top Countries Contributing to Clinical Trials in Central and South America 14
  • Clinical Trials by G7 Countries: Proportion of Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) to Genetic Disorders Clinical Trials 15
  • Clinical Trials by Phase in G7 Countries 17
  • Clinical Trials in G7 Countries by Trial Status 18
  • Clinical Trials by E7 Countries: Proportion of Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) to Genetic Disorders Clinical Trials 20
  • Clinical Trials by Phase in E7 Countries 22
  • Clinical Trials in E7 Countries by Trial Status 23
  • Clinical Trials by Phase 24
  • In Progress Trials by Phase 25
  • Clinical Trials by Trial Status 26
  • Clinical Trials by End Point Status 28
  • Subjects Recruited Over a Period of Time 29
  • Clinical Trials by Sponsor Type 30
  • Prominent Sponsors 31
  • Top Companies Participating in Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials 33
  • Prominent Drugs 35
  • Clinical Trial Profile Snapshots 37

Appendix 71

  • Abbreviations 71
  • Definitions 71
  • Research Methodology 72
  • Secondary Research 72
  • About GlobalData 72
  • Contact Us 73
  • Source 73